Legis Daily

NIH Clinical Trial Diversity Act of 2022

USA117th CongressS-5268| Senate 
| Updated: 12/15/2022
Robert Menendez

Robert Menendez

Democratic Senator

New Jersey

Cosponsors (1)
Susan M. Collins (Republican)

Health, Education, Labor, and Pensions Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
NIH Clinical Trial Diversity Act of 2022 This bill sets out requirements to increase the diversity of clinical trial participants. The bill also requires other activities to foster participation in clinical trials. As a condition of funding from the National Institutes of Health (NIH) for a clinical trial investigating a drug or device, a sponsor's application must include certain information related to diversity in its trial, such as goals for recruiting and retaining trial participants and plans for achieving the recruitment and retention goals and implementing less-burdensome clinical trial follow-up requirements. A sponsor must also annually share demographic data of clinical trial participants with the NIH. Further, the NIH and the Food and Drug Administration must carry out a national campaign to increase awareness about the need for diverse clinical trials.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 20, 2022

Latest Companion Bill Action

HR 117-7845
Referred to the Subcommittee on Health.
Dec 15, 2022
Introduced in Senate
Dec 15, 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 20, 2022

    Latest Companion Bill Action

    HR 117-7845
    Referred to the Subcommittee on Health.


  • December 15, 2022
    Introduced in Senate


  • December 15, 2022
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health

NIH Clinical Trial Diversity Act of 2022

USA117th CongressS-5268| Senate 
| Updated: 12/15/2022
NIH Clinical Trial Diversity Act of 2022 This bill sets out requirements to increase the diversity of clinical trial participants. The bill also requires other activities to foster participation in clinical trials. As a condition of funding from the National Institutes of Health (NIH) for a clinical trial investigating a drug or device, a sponsor's application must include certain information related to diversity in its trial, such as goals for recruiting and retaining trial participants and plans for achieving the recruitment and retention goals and implementing less-burdensome clinical trial follow-up requirements. A sponsor must also annually share demographic data of clinical trial participants with the NIH. Further, the NIH and the Food and Drug Administration must carry out a national campaign to increase awareness about the need for diverse clinical trials.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
May 20, 2022

Latest Companion Bill Action

HR 117-7845
Referred to the Subcommittee on Health.
Dec 15, 2022
Introduced in Senate
Dec 15, 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • May 20, 2022

    Latest Companion Bill Action

    HR 117-7845
    Referred to the Subcommittee on Health.


  • December 15, 2022
    Introduced in Senate


  • December 15, 2022
    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Robert Menendez

Robert Menendez

Democratic Senator

New Jersey

Cosponsors (1)
Susan M. Collins (Republican)

Health, Education, Labor, and Pensions Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted